These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 11701763)

  • 1. Vaccination with soluble Abeta oligomers generates toxicity-neutralizing antibodies.
    Lambert MP; Viola KL; Chromy BA; Chang L; Morgan TE; Yu J; Venton DL; Krafft GA; Finch CE; Klein WL
    J Neurochem; 2001 Nov; 79(3):595-605. PubMed ID: 11701763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonhuman amyloid oligomer epitope reduces Alzheimer's-like neuropathology in 3xTg-AD transgenic mice.
    Rasool S; Martinez-Coria H; Milton S; Glabe CG
    Mol Neurobiol; 2013 Dec; 48(3):931-40. PubMed ID: 23771815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neutralization of soluble, synaptotoxic amyloid β species by antibodies is epitope specific.
    Zago W; Buttini M; Comery TA; Nishioka C; Gardai SJ; Seubert P; Games D; Bard F; Schenk D; Kinney GG
    J Neurosci; 2012 Feb; 32(8):2696-702. PubMed ID: 22357853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The conformational epitope for a new Aβ42 protofibril-selective antibody partially overlaps with the peptide N-terminal region.
    Colvin BA; Rogers VA; Kulas JA; Ridgway EA; Amtashar FS; Combs CK; Nichols MR
    J Neurochem; 2017 Dec; 143(6):736-749. PubMed ID: 28881033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Globular amyloid beta-peptide oligomer - a homogenous and stable neuropathological protein in Alzheimer's disease.
    Barghorn S; Nimmrich V; Striebinger A; Krantz C; Keller P; Janson B; Bahr M; Schmidt M; Bitner RS; Harlan J; Barlow E; Ebert U; Hillen H
    J Neurochem; 2005 Nov; 95(3):834-47. PubMed ID: 16135089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting small Abeta oligomers: the solution to an Alzheimer's disease conundrum?
    Klein WL; Krafft GA; Finch CE
    Trends Neurosci; 2001 Apr; 24(4):219-24. PubMed ID: 11250006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A vaccine with Aβ oligomer-specific mimotope attenuates cognitive deficits and brain pathologies in transgenic mice with Alzheimer's disease.
    Wang SW; Liu DQ; Zhang LX; Ji M; Zhang YX; Dong QX; Liu SY; Xie XX; Liu RT
    Alzheimers Res Ther; 2017 Jun; 9(1):41. PubMed ID: 28592267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strikingly reduced amyloid burden and improved behavioral performance in Alzheimer's disease mice immunized with recombinant chimeric vaccines by hexavalent foldable Aβ₁₋₁₅ fused to toxin-derived carrier proteins.
    Yu YZ; Wang WB; Chen A; Chang Q; Liu S; Zhao M; Wang S; Qiu WY; Pang XB; Xu Q; Sun ZW
    J Alzheimers Dis; 2014; 41(1):243-60. PubMed ID: 24625800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis.
    Kayed R; Head E; Thompson JL; McIntire TM; Milton SC; Cotman CW; Glabe CG
    Science; 2003 Apr; 300(5618):486-9. PubMed ID: 12702875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decoding the synaptic dysfunction of bioactive human AD brain soluble Aβ to inspire novel therapeutic avenues for Alzheimer's disease.
    Li S; Jin M; Liu L; Dang Y; Ostaszewski BL; Selkoe DJ
    Acta Neuropathol Commun; 2018 Nov; 6(1):121. PubMed ID: 30409172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Physicochemical characteristics of soluble oligomeric Abeta and their pathologic role in Alzheimer's disease.
    Watson D; Castaño E; Kokjohn TA; Kuo YM; Lyubchenko Y; Pinsky D; Connolly ES; Esh C; Luehrs DC; Stine WB; Rowse LM; Emmerling MR; Roher AE
    Neurol Res; 2005 Dec; 27(8):869-81. PubMed ID: 16354549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccination with a non-human random sequence amyloid oligomer mimic results in improved cognitive function and reduced plaque deposition and micro hemorrhage in Tg2576 mice.
    Rasool S; Albay R; Martinez-Coria H; Breydo L; Wu J; Milton S; Misra S; Tran A; Pensalfini A; Laferla F; Kayed R; Glabe CG
    Mol Neurodegener; 2012 Aug; 7():37. PubMed ID: 22866920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monoclonal antibodies that target pathological assemblies of Abeta.
    Lambert MP; Velasco PT; Chang L; Viola KL; Fernandez S; Lacor PN; Khuon D; Gong Y; Bigio EH; Shaw P; De Felice FG; Krafft GA; Klein WL
    J Neurochem; 2007 Jan; 100(1):23-35. PubMed ID: 17116235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenic properties of amyloid beta oligomers.
    Dalgediene I; Lasickiene R; Budvytyte R; Valincius G; Morkuniene R; Borutaite V; Zvirbliene A
    J Biomed Sci; 2013 Feb; 20(1):10. PubMed ID: 23432787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conformation-sensitive antibodies against alzheimer amyloid-beta by immunization with a thioredoxin-constrained B-cell epitope peptide.
    Moretto N; Bolchi A; Rivetti C; Imbimbo BP; Villetti G; Pietrini V; Polonelli L; Del Signore S; Smith KM; Ferrante RJ; Ottonello S
    J Biol Chem; 2007 Apr; 282(15):11436-45. PubMed ID: 17267402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the neurotoxic species in Alzheimer's disease: inhibitors of Abeta oligomerization.
    De Felice FG; Vieira MN; Saraiva LM; Figueroa-Villar JD; Garcia-Abreu J; Liu R; Chang L; Klein WL; Ferreira ST
    FASEB J; 2004 Sep; 18(12):1366-72. PubMed ID: 15333579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Formation of highly toxic soluble amyloid beta oligomers by the molecular chaperone prefoldin.
    Sakono M; Zako T; Ueda H; Yohda M; Maeda M
    FEBS J; 2008 Dec; 275(23):5982-93. PubMed ID: 19021772
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abeta toxicity in Alzheimer's disease: globular oligomers (ADDLs) as new vaccine and drug targets.
    Klein WL
    Neurochem Int; 2002 Nov; 41(5):345-52. PubMed ID: 12176077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lack of P-glycoprotein Results in Impairment of Removal of Beta-Amyloid and Increased Intraparenchymal Cerebral Amyloid Angiopathy after Active Immunization in a Transgenic Mouse Model of Alzheimer's Disease.
    Bruckmann S; Brenn A; Grube M; Niedrig K; Holtfreter S; von Bohlen und Halbach O; Groschup M; Keller M; Vogelgesang S
    Curr Alzheimer Res; 2017; 14(6):656-667. PubMed ID: 27915995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting generation of antibodies specific to conformational epitopes of amyloid beta-derived neurotoxins.
    Lambert MP; Velasco PT; Viola KL; Klein WL
    CNS Neurol Disord Drug Targets; 2009 Mar; 8(1):65-81. PubMed ID: 19275637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.